Cell Therapy Cdmo Market: Market Size & Forecast 2026

The cell therapy CDMO market provides end-to-end support for biopharmaceutical companies seeking to bring cell-based treatments to market without building in-house manufacturing capacity. Services span process development, cell line characterization, clinical and commercial-scale manufacturing, quality control testing, and regulatory filing support. The sector has grown alongside the broader cell and gene therapy industry, driven by the technical complexity of manufacturing living cell products that require stringent GMP compliance, cold-chain logistics, and highly trained personnel.

• •Services range from early-stage process development to large-scale commercial manufacturing for CAR-T, TCR, stem cell, and other cell-based therapies
• •CDMOs help sponsors navigate complex regulatory pathways for cell therapy products, which require specialized expertise in GMP compliance and quality systems
• •The market encompasses pure-play cell therapy specialists as well as large, diversified CDMOs serving both cell and gene therapy clients

Rising prevalence of cancer and increasing adoption of immunotherapies, particularly CAR-T cell therapies, are primary catalysts for market growth. The expanding pipeline of cell therapy candidates moving from clinical trials to commercialization is driving sustained demand for CDMO manufacturing capacity and process development expertise. Additionally, the high cost and technical complexity of building and maintaining cell therapy manufacturing facilities in-house continue to push biopharmaceutical companies toward outsourcing partnerships.

• •Over 1,000 active cell therapy clinical trials globally are underway, most of which rely on CDMO manufacturing support
• •Regulatory designations such as breakthrough therapy status and accelerated approvals are shortening development timelines, increasing throughput demand for CDMO services
• •Pharmaceutical companies lacking cell therapy manufacturing expertise increasingly outsource to avoid capital expenditure and technical risk

The market is segmented by service type into stem-cell based therapies, non-stem-cell based therapies (including CAR-T and TCR-based immunotherapies), and other emerging modalities. By supply stage, services are divided between clinical-stage manufacturing support and commercial-scale production. Geographically, North America holds the largest market share, supported by a high concentration of biopharmaceutical companies, favorable regulatory frameworks, and significant R&D investment.

• •North America leads the global market, with the United States accounting for the majority of cell therapy CDMO revenue driven by FDA-approved CAR-T products and a robust clinical pipeline
• •Europe represents the second-largest regional market, with strong activity in the United Kingdom, Germany, and France focused on cell therapy innovation and manufacturing expansion
• •Asia-Pacific is emerging as the fastest-growing region, led by Japan, South Korea, and China, as local regulatory agencies advance cell therapy approval pathways

What are the recent trends and outlook?

Looking ahead, the cell therapy CDMO market is expected to continue its double-digit growth trajectory as more cell therapies progress through clinical trials and reach commercial approval. Advances in allogeneic (off-the-shelf) cell therapies, automated cell processing technologies, and closed-system manufacturing are reshaping service offerings and capacity planning across the industry. CDMOs that invest in next-generation manufacturing platforms and strategic geographic expansion are positioned to capture the largest share of growing demand.

• •The shift toward allogeneic cell therapies is creating new manufacturing requirements and capacity needs for CDMOs focused on large-scale, standardized production
• •Advances in automated cell processing and closed-system manufacturing technologies are improving efficiency, reducing contamination risk, and enabling higher throughput
• •With a compound annual growth rate of 19.0%, the market is projected to continue expanding significantly through 2030 and beyond as approved therapies drive commercial manufacturing demand